AtriCure, Inc. (NASDAQ:ATRC) Q2 2023 Earnings Conference Call July 25, 2023 4:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin Group Mike Carrel - President & CEO Angie Wirick - CFO Conference Call Participants Robert Marcus - J.P. Morgan William Plovanic - Canaccord Matthew O’Brien - Piper Sandler Marie Thibault - BTIG Frederick Wise - Stifel Michael Matson - Needham Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome to AtriCure's Second Quarter 2023 Earnings Conference Cal ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.001 par value ATRC NASDAQ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________ FORM 10-Q ___________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ¨ TRANSITION REP ...

AtriCure, Inc. (NASDAQ:ATRC) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Marissa Bych – Vice President-Gilmartin Group Mike Carrel – President and Chief Executive Officer Angie Wirick – Chief Financial Officer Conference Call Participants Matthew O’Brien – Piper Sandler Marie Thibault – BTIG John McAulay – Stifel Joseph Conway – Needham Suraj Kalia – Oppenheimer Operator Good afternoon, and welcome to AtriCure's First Quarter 2023 Earnings Conference Call. At this time, all ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________ FORM 10-Q ___________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________to_ ...

Creating a World Class Platform INVESTOR PRESENTATION Oppenheimer 33rd Annual Healthcare Conference MARCH 2023 ...

AtriCure, Inc. (NASDAQ:ATRC) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - J.P. Morgan Bill Plovanic - Canaccord Marie Thibault - BTIG Mike Matson - Needham Suraj Kalia - Oppenheimer Rick Wise - Stifel Operator Good afternoon, and welcome to AtriCure's Q4 2022 Earnings Conference Cal ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ FORM 10-K _________________________________ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-51470 _______________ AtriCure, Inc. (Exact name of registrant as specified in its charter) _____________ ...

Financial Data and Key Metrics Changes - AtriCure reported Q4 2021 revenue of $73.2 million, reflecting a growth of approximately 27% year-over-year and 4% sequentially [5][17] - Gross margin for Q4 2021 was 75.1%, up 160 basis points from Q4 2020, driven by favorable geographic and product mix [19] - The company experienced an adjusted EBITDA loss of $2.1 million in Q4 2021, compared to a positive adjusted EBITDA of $1.7 million in Q4 2020 [19] - For the full year 2021, worldwide revenue was $274.3 million, an increase of 32.8% on a reported basis [20] - The full year adjusted EBITDA loss was $8.8 million, compared to a loss of $6.3 million in 2020 [22] Business Line Data and Key Metrics Changes - The pain management franchise, particularly the Cryo Nerve Block, has become one of the fastest-growing therapies, with significant expansion in the U.S. market [12][13] - The appendage management franchise, led by the AtriClip product line, grew 39% in 2021, with record sales of AtriClip Flex-V devices [11] - The Hybrid AF therapy franchise saw significant growth, with the company estimating that approximately 45% of diagnosed Afib patients are long-standing persistent, presenting a unique market opportunity [8] Market Data and Key Metrics Changes - U.S. revenue for Q4 2021 was $61.2 million, a 29.1% increase from Q4 2020, reflecting healthy activity across product lines [17] - International revenue totaled $12 million, up 16.3% on a reported basis, with Europe, the Middle East, and Africa accounting for $7.4 million [18] - The company anticipates first quarter 2022 revenue to be down slightly from Q4 2021 due to ongoing staffing challenges and the impact of Omicron [24] Company Strategy and Development Direction - AtriCure is focused on expanding its Hybrid AF therapy and has plans to deepen penetration in the cardiac surgery market with the EnCompass device [10][11] - The company aims to leverage its unique physician relationships and expand into markets complementary to treating complex arrhythmias [14] - AtriCure is committed to ongoing clinical innovation and regulatory developments, including the submission of the LEAPS protocol to the FDA [13][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing challenges from the COVID-19 pandemic, including staffing shortages and capacity constraints impacting procedure volumes [7] - The company remains optimistic about growth in 2022, reaffirming its revenue guidance of $315 million to $330 million [7][23] - Management highlighted the importance of investments in research and development to drive future growth and profitability [25] Other Important Information - AtriCure published its inaugural ESG report, emphasizing its commitment to operating responsibly and sustainably [16] - The company has expanded its commercial team and training efforts to meet demand from the physician community [9] Q&A Session Summary Question: What is the future penetration outlook for the cryoSPHERE probe? - Management indicated that they anticipate reaching double-digit penetration in the cryoSPHERE market as the year progresses, supported by sales force expansion and procedure volume recovery [27][28] Question: What is the outlook for gross margin improvement? - Management noted that while gross margin is expected to be similar to 2021, there are headwinds from investments in production capacity and inflation pressures [30][31] Question: How is the minimally invasive segment expected to grow? - Management expects the minimally invasive segment, particularly the CONVERGE and EPi-Sense products, to grow above historical rates, driven by increased adoption and demand [34][35] Question: What metrics will indicate productivity from new accounts? - Management will monitor repeat buyers and the establishment of collaborative programs at new sites to gauge productivity, rather than focusing solely on revenue from new accounts [51][53] Question: What is the expected impact of the CE mark for Cryo in Europe? - Management expressed excitement about the CE mark for Cryo but indicated that significant impact in 2022 is unlikely, with expectations for a more substantial rollout in 2023 and 2024 [70]

Market Opportunity - AtriCure addresses a large global Afib market, with over 33 million patients worldwide[12, 60] - The US market opportunity is estimated at over $3 billion annually, while the international market presents a $2 billion+ opportunity[14] - The company estimates that the standalone Afib market includes over 3 million patients, with less than 1% currently treated[21] Financial Performance & Growth - The company's revenue guidance for 2022 is between $315 million and $330 million, representing a year-over-year growth of 15-20%[54] - Historically, AtriCure has demonstrated strong revenue growth, with a 5-year organic revenue CAGR of approximately 15%[54] - U S AtriClip has a 5-Year historical organic revenue CAGR ~32%[54] Product Portfolio & Clinical Evidence - The company's AtriClip device has over 300,000 units sold to date[24, 60] - The CONVERGE trial demonstrated superior outcomes with the hybrid Convergent procedure compared to endocardial catheter ablation alone in patients with drug-refractory long-standing persistent Afib, with a 29% differential improvement[29] - Cryo Nerve Block therapy accounted for approximately 8% of AtriCure's worldwide revenue in 2021, up from approximately 5% in 2020[45]

AtriCure, Inc. (NASDAQ:ATRC) Q3 2020 Results Conference Call November 5, 2020 4:30 PM ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President and CEO Angie Wirick - CFO Conference Call Participants Robby Marcus - JP Morgan Rick Wise - Stifel Danielle Antalffy - SVB Leerink Matthew O’Brien - Piper Sandler Mike Matson - Needham & Company Marie Thibault - BTIG Bill Plovanic - Canaccord Operator Good afternoon and welcome to AtriCure’s Third Quarter 2020 Earnings Conference Call. At this ti ...